Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study
Transplant International · 2024
DOI: 10.3389/ti.2024.13245 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Transplant International, 2024. Verfasst von Renato Pascale und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Lung Transplantation, Antibiotic Prophylaxis, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Perioperative antibiotic prophylaxis (PAP) in lung transplant recipients (LuTRs) has high heterogeneity between centers. Our aim was to investigate retrospectively the approach to PAP in our center over a 20-year period (2002–2023), and its impact on early post-operative infections (EPOIs) after lung transplantation (LuT). Primary endpoint was diagnosis of EPOI, defined as any bacterial infection including donor-derived events diagnosed within 30 days from LuT. Main exposure variables were type of PAP (combination vs. monotherapy) and PAP duration. We enrolled 111 LuTRs. PAP consisted of single-agent or combination regimens in 26 (25.2%) and 85 (74.8%) LuTR. Median PAP duration was 10 days (IQR 6–13) days. Piperacillin/tazobactam was the most common agent used either as monotherapy (n = 21, 80.7%) or as combination with levofloxacin (n = 79, 92.9%). EPOIs were diagnosed in 30 (27%) patients. At multivariable analysis no advantages were found for combination regimens compared to single-agent PAP in preventing EPOI (OR: 1.57, 95% CI: 0.488–5.068, p:0.448). The impact of PAP duration on EPOIs development was investigated including duration of PAP ≤6 days as main exposure variables, without finding a significantly impact (OR:2.165, 95% CI: 0.596–7.863, p: 0.240). Our results suggest no advantages for combination regimens PAP in preventing EPOI in LuTR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Infectious Diseases Unit, Scientific Institute for Research, Hospitalization and Healthcare Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Division of Interventional Pulmonology Unit, Scientific Institute for Research, Hospitalization and Healthcare Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Thoracic Surgery, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy.
- Thoracic Surgery, Scientific Institute for Research, Hospitalization and Healthcare Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Anaesthesiology and Intensive Care, Scientific Institute for Research, Hospitalization and Healthcare Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Förderung
- Ministero della Salute
Zitieren
APA
Pascale, R., Tazza, B., Amicucci, A., Salvaterra, E., Dolci, G., Antonacci, F., Baiocchi, M., Pastore, S., Ambretti, S., Peghin, M., Viale, P., & Giannella, M. (2024). Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study. Transplant International. https://doi.org/10.3389/ti.2024.13245
Vancouver
Pascale R, Tazza B, Amicucci A, Salvaterra E, Dolci G, Antonacci F, et al. Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study. Transplant International. 2024. doi:10.3389/ti.2024.13245
BibTeX
@article{Pascale2024,
author = {Pascale, Renato and Tazza, Beatrice and Amicucci, Armando and Salvaterra, Elena and Dolci, Giampiero and Antonacci, Filippo and Baiocchi, Massimo and Pastore, Saverio and Ambretti, Simone and Peghin, Maddalena and Viale, Pierluigi and Giannella, Maddalena},
title = {Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13245}
}
EUVIMED